Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer

Annals of Oncology

Volumn 18, Issue 6, 2007, Pages 977-984

  Valabrega, Giorgio ^a   Montemurro, F ^a   Aglietta, M ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Breast neoplasms; HER2; Mechanism of action; Resistance; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPITOPE; EVEROLIMUS; GEFITINIB; LAPATINIB; LIGAND; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOMEDIN C RECEPTOR; TAXANE DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB;

ANGIOGENESIS; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TREATMENT FAILURE; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 34447306848     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl475     Document Type: Review

References (68)

1. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HEH-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Bel 2001; 2: 127-137.
3. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 1987; 84; 7159-7163.
4. Faltus T, Yuan J, Zimmer B et al. Silencing of the HLR2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/ neu-overexpressing breast cancer cells. Neoplasia 2004; 6: 786-795.
5. Chouchury A. Kiessling R. Her-2/neu is a paradigm of a tumor-specite for therapy. Breast Dis 2004; 20: 25-31.
6. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of tho HER-2/neu oncogene Science 1987; 235: 177-182.
7. Montemurro F, Aglietta M. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. Clin Breast Cancer 2005; 6: 77-80.
8. Montemurro F, Valabrega G, Aglietta M. Trastuzumab-based combination therapy for breast cancer. Expert Opin Pharmacother 2004; 5: 81-96.
9. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HFR2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-192.
10. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment: The M77001 stdy group. J Clin Oncol 2005 23: 4265-4274.
11. Remand EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. IN Engl J Med 2005; 353: 1673-1684.
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
13. Slamon D, Eiermann W, Robert N et al. Phase III randomized Vial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACT) with docetaxei, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study, Breast Cancer Res Treat 200b; 94: S5 (Abstr 1).
14. Press MI. Slamon DJ. Hom KJ et al. Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20: 3095-3105.
15. fornier M. Risio M. Van PC et al. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park) 2002; 16: 1340-1342.
16. Pauletti G, Dandekar, S, Rong H et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of flourescence in situ hybridization and immunohistochemistry J Clin Oncol 2000; 18: 3651-3664.
17. Gancberg D, Jarvinen T, Di et al. al Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: An interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat 2002; 74: 113-120.
18. Mass RD, Press MF, Anderson S et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005; 6: 240-246.
19. Jacobs IW, Gown AM, Yaziji H et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999; 17: 1983-1987.
20. Cooley S, Burns LJ, Repka et al. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxiciy aains LFA-3 and HER2/neu. Exp Hematol 1999; 27: 1533-1541.
21. LEWIS GD, Figari I, Fendly B et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37: 255-263.
22. Clynes RA, Towers TL, Presta LG et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-446.
23. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10: 5650-5655.
24. Repka T, Chiorean EG, Gay J et al. Trastuzumab and interleukin-2 in HEH2-positive metastatic breast cancer: A pilot study. Clin Cancer Res 2003; 9: 2440-2446,
25. Christianson TA, Doherty JK, Lin YJ et al. NH2-terminaly truncated HER-2/ neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998; 58: 5123-5129.
26. Molina MA, humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749.
27. Fornier MN, Seidman AD, Schwartz MK et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: Association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate Arm Oncol 2005: 16: 234-239.
28. Kostler WJ, Schwab B, Singer CF et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004; 10: 1618-1624.
29. Sarup JC, Johnson RM, King KL et al. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991; 1: 72-82.
30. Valabrega G, Montemurro F, Sarotto I et al. TGFalpha expression impairs trastuzumab-induced HER2 downregulation. Oncogene 2005; 24: 3002-3010.
31. Austin CD, De Maziere AM, Pisacane PI et al. Endocytosis and sorting of ErbB32 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004; 15: 5268-5282.
32. Deland JP, Allal C, Canal M et al. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Ann Oncol 2005; 16: 1889-1897
33. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTFN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127.
34. Yen L, You XL, AI Moustafa AE et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000; 19: 3460-3469.
35. Izumi Y, Xu L, Di TE et al. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-280.
36. Klos KS, Zhou X, Lee S et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003; 98: 1377-1385.
37. Lane HA, Motoyama AB, Beuvink I et al. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol 2001; 12 (Suppl 1): S21-S22.
38. Lu Y, Zi X, Zhao Y et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93: 1852-1857.
39. Nahta R, Yuan LX, Zhang B et al. Insulin-like growth factor-I receptor/ human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65: 11118-11128.
40. Diermeier S, Horvath G, Knuechel-Clarke R et al. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB receptor interaction and activation. Exp Cell Res 2005; 304: 604-619.
41. Nagy P, Friedlander E, Tanner M et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005; 65: 473-482.
42. Bussolati G, Montemurro F. Rigini L et al. A modified trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. Br J Cancer 2005; 92: 1261-1267.
43. Spector NL, Xia W, Burris H, III et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23: 2502-2512.
44. Xia W, Gerard CM, Liu L et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005; 24: 6213-6221.
45. Gomez HL, Chavez MA, Doval DC et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first line treatment in patients with FISH positive advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 2005; 23: 203s (Abstr 3046).
46. Blackwell KL, Burstein H, Pegram M et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. Proc Am Soc Clin Oncol 2005: 23: 193s (Abstr 3004).
47. Spector NL, Blackwell K, Hurley J et al. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory preast cancer (IBC): Clinical activity and biologic predictors of response. Proc Am Soc Clin Oncol 2006; 24: (Abstr 502).
48. Geyer, Cameron, Lindquist et al. A phase III randomized, open label, international study comparing lapatinib and capecitabine vs capecitabine in women with refractory or advanced metastatic breast cancer (EGF 100151). ASCO Scientific Special Session: Lapatinib in Trastuzumab Resistant Breast Cancer. http://www.asco.org (31 August 2006, date last accessed).
49. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. Proc Am Soc Clin Oncol 2006; 24: (Abstr 503).
50. Storniolo AM, Burris H, Pegram M et al. A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. Proc Am Soc Clin Oncol 2005; 23: 559 (Abstr 18s).
51. Normanno N, Campiglio M, De LA et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002; 13: 65-72.
52. Warburton C, Dragowska WH, Gelmon K et al. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): Drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 2004; 10: 2512-2524.
53. Arteaga CL, O'Neil A, Moulder SL et al. ECOG1100: A phase I-II study of combine blockade of the erbB receptor network with trastuzumab and gefitinib ([Isquo]lressa) in patients (pts) with HER2-overexpressing metastatic breast cancer (met br ca). Breast Cancer Res Treat 2004; 88: S15 (Abstr 25).
54. Normanno N, Campiglio M, Perrone I et al. Is the gefitinib plus trastuzumab combination feasible in breast cancer patients? Ann Oncol 2005; 16: 1709.
55. Agus DB, Akita RW, Fox WD et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2: 127-137.
56. Cho HS, Mason K, Ramyar KX et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421: 756-760.
57. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64: 2343-2346.
58. Chan S, Johnston S, Scheulen ME et al. First report: A phase 2 study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy. Proc Am Soc Clin Oncol 2002; 21: 44a (Abstr 175).
59. Pegram MD, Yeon C, Ku NG et al. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 2004; 88: S124 (Abstr 3039).
60. Batra JK, Kasprzyk PG, Bird RE et al. Recombinant anti-erB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA 1992; 89: 5867-5871.
61. Rosenblum MG, Horn SA, Cheung LH. A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor. Int J Cancer 2000; 88: 267-273.
62. Nahta R, Esteva FJ. Herceptin: Mechanisms of action and resistance. Cancer Lett 2006; 232: 123-138.
63. Tan-Chiu E, Kaufman PA, Paik S et al. registHER: A prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer. Proc Am Soc Clin Oncol 2005; 23: 46s (Abstr 670).
64. Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories. Clin Breast Cancer 2004; 5: 52-58.
65. Fountzilas G, Razis E, Tsavdaridis D et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 2003; 4: 120-125.
66. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063-1070.
67. Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006; 11: 318-324.
68. Montemurro F, Faggiuolo R, Redana S et al. Continuation of trastuzumab beyond disease progression. J Clin Oncol 2005; 23: 2866-2868.